Literature DB >> 2838714

Heterogeneous 3H-rauwolscine binding sites in rat cortex: two alpha 2-adrenoceptor subtypes or an additional non-adrenergic interaction?

A M Broadhurst1, B S Alexander, M D Wood.   

Abstract

Ligand binding and isolated tissue data have provided evidence for the existence of two, tissue-specific, alpha 2-adrenoceptor subtypes in various rodent and non-rodent species. Thus it has been proposed that the complex binding of alpha 2-antagonists to rat cortical membranes is due to the presence of both subtypes in this tissue. We have previously shown that the alpha 2-antagonist 3H-rauwolscine binds to two sites on rat cortical membranes: a high affinity component characterised pharmacologically as an alpha 2-binding site, and a low affinity, spiperone-sensitive, serotonergic-like component. By the use of computerised non-linear curve-fitting, and the inclusion of (in the incubation buffer of displacement experiments) a concentration of spiperone previously shown to selectively occlude the low affinity component of the 3H-rauwolscine saturation isotherm, we have determined the rank order of affinity at each of the two sites. Whereas the rank order of affinity at the high affinity site retains the pharmacological profile of a single, monophasic alpha 2-binding site, that at the low affinity component is markedly different and is similar to that at the putative 5HT1A subtype. These data, together with the additional, functional serotonergic interactions of rauwolscine and yohimbine, indicate that there is no evidence to support the existence of heterogeneous alpha 2-binding sites, as measured by 3H-rauwolscine binding, on rat cortical membranes. Furthermore, we present evidence that the specific, low affinity serotonergic interaction of 3H-rauwolscine could be avoided by a more judicial estimation of specific binding.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838714     DOI: 10.1016/0024-3205(88)90240-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  [3H]-MK 912 binding delineates two alpha 2-adrenoceptor subtypes in rat CNS one of which is identical with the cloned pA2d alpha 2-adrenoceptor.

Authors:  S Uhlén; Y Xia; V Chhajlani; C C Felder; J E Wikberg
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.

Authors:  Nicholas L Meyers; Roger I Hickling
Journal:  Drugs R D       Date:  2008

3.  [3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification.

Authors:  A C MacKinnon; A T Kilpatrick; B A Kenny; M Spedding; C M Brown
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

4.  Effects of 5-HT-receptor and alpha 2-adrenoceptor ligands on the haemodynamic response to acute central hypovolaemia in conscious rabbits.

Authors:  R G Evans; J M Haynes; J Ludbrook
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.

Authors:  D Marona-Lewicka; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

6.  Heterogeneity of alpha 2-adrenoceptors in rat cortex but not human platelets can be defined by 8-OH-DPAT, RU 24969 and methysergide.

Authors:  C M Brown; A C MacKinnon; J C McGrath; M Spedding; A T Kilpatrick
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

7.  Assessment of imiloxan as a selective alpha 2B-adrenoceptor antagonist.

Authors:  A D Michel; D N Loury; R L Whiting
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

8.  Effects of sodium, lithium, and magnesium on in vitro binding of [3H]SCH23390 in rat neostriatum and cerebral cortex.

Authors:  E Gottberg; L Diop; B Montreuil; T A Reader
Journal:  Neurochem Res       Date:  1989-05       Impact factor: 3.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.